Subtopic Deep Dive

Dystrophin in Muscle Function
Research Guide

What is Dystrophin in Muscle Function?

Dystrophin is a cytoskeletal protein essential for sarcolemma stability in muscle cells, absent in Duchenne muscular dystrophy (DMD).

Dystrophin links the cytoskeleton to the extracellular matrix via the dystrophin-glycoprotein complex (DGC). Its deficiency causes membrane fragility and muscle degeneration in DMD (Hoffman et al., 1987; 4631 citations). Over 10,000 papers explore its function and therapies, including ~200 on gene therapy.

Curated Papers

Key Challenges

Why It Matters

Dystrophin research enables exon-skipping and gene replacement therapies for DMD, affecting 1 in 3500 males worldwide (Theadom et al., 2014). Stem cell transplantation restores dystrophin in mdx mice, informing clinical trials (Gussoni et al., 1999). DGC studies reveal laminin-actin linkages critical for muscle integrity (Ervasti and Campbell, 1993). These advances target sarcolemma protection during contraction (Petrof et al., 1993), driving treatments for 250,000+ DMD cases globally.

Key Research Challenges

Restoring Full-Length Dystrophin

Gene therapy vectors limit packaging of the 14kb dystrophin gene, restricting delivery efficiency. Mini-dystrophins partially restore function but fail to fully replicate wild-type mechanics (Duan et al., 2021). mdx mouse models show incomplete sarcolemma rescue despite expression (Gussoni et al., 1999).

DGC Protein Interactions

Mapping dystrophin interactions with laminin and actin requires advanced proteomics beyond initial identifications (Ibraghimov-Beskrovnaya et al., 1992). Mutations disrupt transmembrane linking, complicating therapy design (Ervasti and Campbell, 1993). Functional validation in human tissue lags animal models (Blake et al., 2002).

Translating mdx Models to Humans

mdx mice exhibit mild pathology unlike severe human DMD, limiting predictive power (Petrof et al., 1993). Stem cell approaches restore dystrophin but face immune rejection in clinics (Gussoni et al., 1999). Atrophy mechanisms differ, hindering growth therapies (Schiaffino et al., 2013).

Essential Papers

Dystrophin: The protein product of the duchenne muscular dystrophy locus

Eric P. Hoffman, Robert H. Brown, Louis M. Kunkel · 1987 · Cell · 4.6K citations

Prevalence of Muscular Dystrophies: A Systematic Literature Review

Alice Theadom, Miriam Rodrigues, Richard Roxburgh et al. · 2014 · Neuroepidemiology · 2.0K citations

Background: Determining the prevalence of neuromuscular disorders for the general population is important to identify the...

Dystrophin expression in the mdx mouse restored by stem cell transplantation

Emanuela Gussoni, Yuko Soneoka, Corinne D. Strickland et al. · 1999 · Nature · 1.8K citations

Dystrophin protects the sarcolemma from stresses developed during muscle contraction.

Basil J. Petrof, Joseph B. Shrager, Hansell H. Stedman et al. · 1993 · Proceedings of the National Academy of Sciences · 1.5K citations

The protein dystrophin, normally found on the cytoplasmic surface of skeletal muscle cell membranes, is absent in patients with Duchenne muscular dystrophy as well as mdx (X-linked muscular dystrop...

Mechanisms regulating skeletal muscle growth and atrophy

Stefano Schiaffino, Kenneth A. Dyar, Stefano Ciciliot et al. · 2013 · FEBS Journal · 1.4K citations

Skeletal muscle mass increases during postnatal development through a process of hypertrophy, i.e. enlargement of individual muscle fibers, and a similar process may be induced in adult skeletal mu...

Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix

Oxana Ibraghimov‐Beskrovnaya, James M. Ervasti, Cynthia J. Leveille et al. · 1992 · Nature · 1.4K citations

A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin

JM Ervasti, Kevin P. Campbell · 1993 · The Journal of Cell Biology · 1.4K citations

The dystrophin-glycoprotein complex was tested for interaction with several components of the extracellular matrix as well as actin. The 156-kD dystrophin-associated glycoprotein (156-kD dystroglyc...

Reading Guide

Foundational Papers

Start with Hoffman et al. (1987; 4631 citations) for dystrophin discovery, then Petrof et al. (1993; 1495 citations) for sarcolemma function, and Ervasti and Campbell (1993; 1375 citations) for DGC structure.

Recent Advances

Study Duan et al. (2021; 1154 citations) for DMD therapy advances and Theadom et al. (2014; 2046 citations) for prevalence data.

Core Methods

mdx mouse assays (Gussoni et al., 1999); contraction stress testing (Petrof et al., 1993); glycoprotein purification (Ibraghimov-Beskrovnaya et al., 1992).

How PapersFlow Helps You Research Dystrophin in Muscle Function

Discover & Search

Research Agent uses searchPapers('dystrophin sarcolemma stability') to retrieve Hoffman et al. (1987; 4631 citations), then citationGraph reveals 1395-citation Ervasti and Campbell (1993) on DGC-laminin links, and findSimilarPapers expands to Petrof et al. (1993) for contraction stress protection.

Analyze & Verify

Analysis Agent runs readPaperContent on Gussoni et al. (1999) to extract mdx restoration data, verifies stem cell efficacy with verifyResponse (CoVe) against Blake et al. (2002), and uses runPythonAnalysis for GRADE grading of expression levels with statistical t-tests on contraction force metrics from Petrof et al. (1993).

Synthesize & Write

Synthesis Agent detects gaps in mini-dystrophin mechanics via contradiction flagging between Duan et al. (2021) and Hoffman et al. (1987), then Writing Agent applies latexEditText for therapy review sections, latexSyncCitations for 10+ refs, and exportMermaid to diagram DGC interactions from Ervasti and Campbell (1993).

Use Cases

"Plot dystrophin expression vs muscle force in mdx mice from key papers"

Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas/matplotlib on Petrof 1993 + Gussoni 1999 data) → researcher gets force-expression scatterplot with regression stats.

"Draft LaTeX review on dystrophin gene therapy for DMD"

Synthesis Agent → gap detection (Duan 2021) → Writing Agent → latexEditText + latexSyncCitations (Hoffman 1987 et al.) + latexCompile → researcher gets compiled PDF with 15 citations and DGC figure.

"Find code for dystrophin modeling simulations"

Research Agent → paperExtractUrls (Blake 2002) → Code Discovery → paperFindGithubRepo → githubRepoInspect → researcher gets Python sim code for sarcolemma stress from Petrof 1993-inspired models.

Automated Workflows

Deep Research workflow scans 50+ dystrophin papers via searchPapers → citationGraph → structured report on DMD prevalence (Theadom 2014) and therapies (Duan 2021). DeepScan applies 7-step CoVe to verify mdx data from Gussoni (1999) with GRADE checkpoints. Theorizer generates hypotheses on DGC atrophy links from Schiaffino (2013) + Ervasti (1993).

Try Doxa for Dystrophin in Muscle Function Research

Frequently Asked Questions

What defines dystrophin in muscle function?

Dystrophin anchors actin to laminin via DGC at the sarcolemma, preventing contraction-induced tears (Petrof et al., 1993; Hoffman et al., 1987).

What are key methods for dystrophin studies?

mdx mouse models test restoration via stem cells (Gussoni et al., 1999); proteomics map DGC (Ibraghimov-Beskrovnaya et al., 1992); force assays measure sarcolemma stability (Petrof et al., 1993).

What are seminal papers on dystrophin?

Hoffman et al. (1987; 4631 citations) identified dystrophin as DMD gene product; Ervasti and Campbell (1993; 1375 citations) defined DGC laminin links; Gussoni et al. (1999; 1793 citations) showed mdx restoration.

What open problems exist in dystrophin research?

Full-length gene delivery exceeds AAV limits (Duan et al., 2021); human-mdx translation fails due to mild mouse pathology (Petrof et al., 1993); DGC-targeted therapies lack specificity (Blake et al., 2002).